JP2005524612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005524612A5 JP2005524612A5 JP2003554713A JP2003554713A JP2005524612A5 JP 2005524612 A5 JP2005524612 A5 JP 2005524612A5 JP 2003554713 A JP2003554713 A JP 2003554713A JP 2003554713 A JP2003554713 A JP 2003554713A JP 2005524612 A5 JP2005524612 A5 JP 2005524612A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- carbonyl
- hydroxy
- chloro
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000007502 anemia Diseases 0.000 claims 6
- 102000003951 Erythropoietin Human genes 0.000 claims 4
- 108090000394 Erythropoietin Proteins 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 229940105423 erythropoietin Drugs 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- BAGRAOZQKMSXCB-UHFFFAOYSA-N 2-[(1-chloro-4-hydroxy-7-methoxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)N=C(Cl)C2=CC(OC)=CC=C21 BAGRAOZQKMSXCB-UHFFFAOYSA-N 0.000 claims 2
- TWOHDFPODFCUOB-UHFFFAOYSA-N 2-[(4-hydroxy-7-propan-2-yloxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)N=CC2=CC(OC(C)C)=CC=C21 TWOHDFPODFCUOB-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000033444 hydroxylation Effects 0.000 claims 2
- 238000005805 hydroxylation reaction Methods 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- OUQVKRKGTAUJQA-UHFFFAOYSA-N n-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine Chemical compound C1=CC=CC2=C(O)C(C(=O)NCC(=O)O)=NC(Cl)=C21 OUQVKRKGTAUJQA-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- -1 (1-chloro-4-hydroxy-7- (2-propyloxy) isoquinolin-3-yl) -carbonyl Chemical group 0.000 claims 1
- LEINOXRFIYQSFV-ZPGRZCPFSA-N (3s)-n-[(2s)-6-amino-1-(2,2-diphenylethylamino)-1-oxohexan-2-yl]-2-(4-oxo-4-phenylbutanoyl)-3,4-dihydro-1h-isoquinoline-3-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C2=CC=CC=C2CN1C(=O)CCC(=O)C1=CC=CC=C1 LEINOXRFIYQSFV-ZPGRZCPFSA-N 0.000 claims 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- ALMCCXFZTYPBOF-UHFFFAOYSA-N 2-[(1-chloro-4-hydroxy-6-methoxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound ClC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC(OC)=CC=C21 ALMCCXFZTYPBOF-UHFFFAOYSA-N 0.000 claims 1
- RYWPJTOGINUXKL-UHFFFAOYSA-N 2-[(1-chloro-4-hydroxy-6-phenylmethoxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C2=C(O)C(C(=O)NCC(=O)O)=NC(Cl)=C2C=CC=1OCC1=CC=CC=C1 RYWPJTOGINUXKL-UHFFFAOYSA-N 0.000 claims 1
- UZPXOYMIEKORSO-UHFFFAOYSA-N 2-[(1-chloro-4-hydroxy-6-propan-2-yloxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound ClC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC(OC(C)C)=CC=C21 UZPXOYMIEKORSO-UHFFFAOYSA-N 0.000 claims 1
- NMKFGLDVALULFJ-UHFFFAOYSA-N 2-[(1-chloro-4-hydroxy-7-phenylmethoxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC2=C(O)C(C(=O)NCC(=O)O)=NC(Cl)=C2C=C1OCC1=CC=CC=C1 NMKFGLDVALULFJ-UHFFFAOYSA-N 0.000 claims 1
- UNZIXZKBJVFYAO-UHFFFAOYSA-N 2-[(1-chloro-4-hydroxy-7-propan-2-yloxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)N=C(Cl)C2=CC(OC(C)C)=CC=C21 UNZIXZKBJVFYAO-UHFFFAOYSA-N 0.000 claims 1
- KWUMPJUJWPWEIN-UHFFFAOYSA-N 2-[(7-butoxy-1-chloro-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)N=C(Cl)C2=CC(OCCCC)=CC=C21 KWUMPJUJWPWEIN-UHFFFAOYSA-N 0.000 claims 1
- IIMCYUKMFLGQFB-UHFFFAOYSA-N 2-[(7-butoxy-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)N=CC2=CC(OCCCC)=CC=C21 IIMCYUKMFLGQFB-UHFFFAOYSA-N 0.000 claims 1
- WAYDNPKLQYUNMN-UHFFFAOYSA-N 2-[(8-chloro-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid Chemical compound ClC1=CC=CC2=C(O)C(C(=O)NCC(=O)O)=NC=C21 WAYDNPKLQYUNMN-UHFFFAOYSA-N 0.000 claims 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 102100037249 Egl nine homolog 1 Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims 1
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims 1
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33708201P | 2001-12-06 | 2001-12-06 | |
| US34965902P | 2002-01-16 | 2002-01-16 | |
| US35968302P | 2002-02-25 | 2002-02-25 | |
| US38648802P | 2002-06-05 | 2002-06-05 | |
| PCT/US2002/039163 WO2003053997A2 (en) | 2001-12-06 | 2002-12-06 | Methods of increasing endogenous erythropoietin (epo) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005351153A Division JP4804131B2 (ja) | 2001-12-06 | 2005-12-05 | 内因性エリスロポエチン（ｅｐｏ）を増加させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005524612A JP2005524612A (ja) | 2005-08-18 |
| JP2005524612A5 true JP2005524612A5 (enExample) | 2006-01-26 |
Family
ID=27502557
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554713A Pending JP2005524612A (ja) | 2001-12-06 | 2002-12-06 | 内因性エリスロポエチン（ｅｐｏ）を増加させる方法 |
| JP2003550737A Expired - Lifetime JP5341293B2 (ja) | 2001-12-06 | 2002-12-06 | 低酸素誘導性因子（ＨＩＦ）−αの安定化 |
| JP2005351153A Expired - Lifetime JP4804131B2 (ja) | 2001-12-06 | 2005-12-05 | 内因性エリスロポエチン（ｅｐｏ）を増加させる方法 |
| JP2010208681A Expired - Lifetime JP5469572B2 (ja) | 2001-12-06 | 2010-09-17 | 内因性エリスロポエチン（ｅｐｏ）を増加させる方法 |
| JP2010243226A Expired - Lifetime JP5498918B2 (ja) | 2001-12-06 | 2010-10-29 | 低酸素誘導性因子（ＨＩＦ）−αの安定化 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550737A Expired - Lifetime JP5341293B2 (ja) | 2001-12-06 | 2002-12-06 | 低酸素誘導性因子（ＨＩＦ）−αの安定化 |
| JP2005351153A Expired - Lifetime JP4804131B2 (ja) | 2001-12-06 | 2005-12-05 | 内因性エリスロポエチン（ｅｐｏ）を増加させる方法 |
| JP2010208681A Expired - Lifetime JP5469572B2 (ja) | 2001-12-06 | 2010-09-17 | 内因性エリスロポエチン（ｅｐｏ）を増加させる方法 |
| JP2010243226A Expired - Lifetime JP5498918B2 (ja) | 2001-12-06 | 2010-10-29 | 低酸素誘導性因子（ＨＩＦ）−αの安定化 |
Country Status (12)
| Country | Link |
|---|---|
| US (15) | US20030153503A1 (enExample) |
| EP (7) | EP2289531B1 (enExample) |
| JP (5) | JP2005524612A (enExample) |
| CN (7) | CN100522946C (enExample) |
| AU (3) | AU2002362065B2 (enExample) |
| CA (4) | CA2916093C (enExample) |
| DK (3) | DK2289531T3 (enExample) |
| ES (3) | ES2414706T3 (enExample) |
| HU (1) | HU229475B1 (enExample) |
| IL (2) | IL162085A0 (enExample) |
| NO (1) | NO343732B1 (enExample) |
| WO (2) | WO2003049686A2 (enExample) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855510B2 (en) * | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| EP1379630B1 (en) * | 2001-03-21 | 2012-09-26 | Isis Innovation Limited | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| US8318703B2 (en) | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
| CN100522946C (zh) * | 2001-12-06 | 2009-08-05 | 法布罗根股份有限公司 | 低氧诱导因子(HIF)α的稳定化 |
| EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| CN103145616B (zh) * | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| WO2005007192A2 (en) * | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| EP1658074B1 (en) * | 2003-08-01 | 2012-11-07 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| WO2005034929A2 (en) * | 2003-10-10 | 2005-04-21 | Fibrogen, Inc. | Tissue remodeling and vascularization |
| US20050170019A1 (en) * | 2003-10-22 | 2005-08-04 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in cells |
| US20050136125A1 (en) * | 2003-10-22 | 2005-06-23 | Roth Mark B. | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms |
| CN1901795B (zh) * | 2003-10-22 | 2014-03-26 | 弗雷德哈钦森癌症研究中心 | 用于在细胞，组织，器官，和有机体中诱导停滞的方法，组合物和装置 |
| US7248843B2 (en) * | 2003-11-07 | 2007-07-24 | Ge Medical Systems Information Technologies, Inc. | Antenna selection system and method |
| EP1548031A1 (en) * | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
| US20050282751A1 (en) * | 2004-03-19 | 2005-12-22 | Ajinomoto Co., Inc. | Therapeutic agent for renal anemia |
| US7638295B2 (en) * | 2004-03-26 | 2009-12-29 | Isis Innovation Limited | Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxygenase and methods of using the same |
| ES2332798T3 (es) * | 2004-05-28 | 2010-02-12 | Fibrogen, Inc. | Ensayo de actividad de la prolil hidroxilasa de hif. |
| US7718624B2 (en) * | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
| US20060074182A1 (en) * | 2004-09-30 | 2006-04-06 | Depuy Products, Inc. | Hydrogel composition and methods for making the same |
| WO2006084210A2 (en) * | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
| CN101166745A (zh) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| AR055319A1 (es) * | 2005-03-17 | 2007-08-15 | Wyeth Corp | Derivados de isoquinoleina, composiciones farmaceuticas y usos |
| PT1879599E (pt) * | 2005-04-20 | 2014-01-23 | Hutchinson Fred Cancer Res | Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos |
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| JP5390184B2 (ja) * | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
| CN101242817B (zh) | 2005-06-15 | 2016-08-31 | 菲布罗根公司 | HIF1α调节剂在治疗癌症中的用途 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| GB0519605D0 (en) * | 2005-09-26 | 2005-11-02 | Isis Innovation | Assay |
| US20090176726A1 (en) * | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| CN100418574C (zh) * | 2005-10-26 | 2008-09-17 | 王成球 | 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽 |
| MX2008006626A (es) | 2005-11-23 | 2008-09-24 | Acceleron Pharma Inc | Antagonistas de activin-actriia y usos para promover el crecimiento de huesos. |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US20070122448A1 (en) * | 2005-11-28 | 2007-05-31 | Alireza Rezania | Compositions and methods to create a vascularized environment for cellular transplantation |
| US7728130B2 (en) * | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
| EP2044028B1 (en) * | 2006-01-27 | 2012-05-16 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| US20070185045A1 (en) * | 2006-02-06 | 2007-08-09 | Ratcliffe Peter J | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| KR20080097446A (ko) | 2006-02-16 | 2008-11-05 | 피브로겐, 인크. | 뇌졸중의 치료를 위한 화합물과 방법 |
| US7588924B2 (en) * | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| US20070293575A1 (en) * | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| US7713986B2 (en) * | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| EP2044005B8 (en) * | 2006-06-26 | 2012-12-05 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
| CN101610793B (zh) | 2006-09-14 | 2012-10-24 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| WO2008040002A2 (en) * | 2006-09-28 | 2008-04-03 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for hif modulating compounds |
| US7635715B2 (en) * | 2006-12-18 | 2009-12-22 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| AU2007334321B2 (en) | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| CL2008000065A1 (es) * | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| US7601399B2 (en) | 2007-01-31 | 2009-10-13 | Surface Modification Systems, Inc. | High density low pressure plasma sprayed focal tracks for X-ray anodes |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| US7618938B2 (en) * | 2007-02-07 | 2009-11-17 | Academia Sinica | Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| WO2008130600A2 (en) | 2007-04-18 | 2008-10-30 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| CA2685219C (en) * | 2007-05-04 | 2012-06-19 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| EP2150251B9 (en) | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| FI20075320A0 (fi) * | 2007-05-07 | 2007-05-07 | Panu Jaakkola | Uusia käyttökelpoisia inhibiittoreita |
| US8962530B2 (en) | 2007-06-27 | 2015-02-24 | Regents Of The University Of Colorado | Inflammatory bowel disease therapies |
| WO2009041072A1 (ja) | 2007-09-27 | 2009-04-02 | Kowa Company, Ltd. | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び／又は治療剤 |
| EP2205741A2 (en) * | 2007-10-02 | 2010-07-14 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
| AU2008319229A1 (en) * | 2007-11-02 | 2009-05-07 | Fibrogen, Inc. | Methods for reducing blood pressure |
| WO2009073497A2 (en) * | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CN101932324A (zh) * | 2007-11-30 | 2010-12-29 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US8536123B2 (en) * | 2008-01-09 | 2013-09-17 | Health Onvector Inc. | Use of blood flow parameters to monitor or control the dosing of erythropoiesis-stimulating agents |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| US8471024B2 (en) * | 2008-02-25 | 2013-06-25 | Merck Sharp & Dohme, Corp. | Tetrahydrofuropyridones |
| EP2303309A2 (en) * | 2008-05-22 | 2011-04-06 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| HRP20191109T1 (hr) | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
| US8217043B2 (en) * | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2010024911A1 (en) * | 2008-08-26 | 2010-03-04 | Fibrogen, Inc. | Methods for increasing neurogenesis |
| EP2341904A1 (en) * | 2008-08-26 | 2011-07-13 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
| US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
| NZ592741A (en) | 2008-11-14 | 2013-03-28 | Fibrogen Inc | Thiochromene derivatives as hif hydroxylase inhibitors |
| CN102317458B (zh) * | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
| EP2415764A4 (en) | 2009-03-31 | 2012-08-08 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE |
| AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| KR101882521B1 (ko) * | 2009-08-13 | 2018-07-27 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| US9205129B2 (en) * | 2009-10-09 | 2015-12-08 | University Of Rochester | Methods of treatment and screening assays for HIF-1α regulation |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| TW201124397A (en) | 2009-10-21 | 2011-07-16 | Daiichi Sankyo Co Ltd | 5-hydroxypyrimidine-4-carboxamide derivatives having a hydrocarbon ring group |
| WO2011056725A1 (en) * | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| ES2424122T3 (es) | 2009-11-06 | 2013-09-27 | Aerpio Therapeutics Inc. | Inhibidores de la prolilhidroxilasa |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| EP3199623B1 (en) | 2010-03-31 | 2021-07-28 | The Scripps Research Institute | Reprogramming cells |
| CN103260649A (zh) | 2010-06-15 | 2013-08-21 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| US9446031B2 (en) | 2012-01-18 | 2016-09-20 | National University Of Singapore | Compositions and methods for neovascularization |
| CA2866556C (en) | 2012-03-09 | 2020-01-07 | Fibrogen, Inc. | 4 -hydroxy-isoquinoline compounds as hif hydroxylase inhibitors |
| EP2822545A4 (en) * | 2012-03-09 | 2015-08-12 | Fibrogen Inc | TREATMENT OF HIGH RATE OF CHOLESTEROL |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| PL2872488T3 (pl) | 2012-07-16 | 2019-01-31 | Fibrogen, Inc. | Postacie krystaliczne inhibitora hydroksylazy prolilowej |
| CN103435546B (zh) | 2012-07-16 | 2016-08-10 | 菲布罗根有限公司 | 制备异喹啉化合物的方法 |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| JP6437456B2 (ja) | 2013-01-24 | 2018-12-12 | フィブロジェン インコーポレイテッド | ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態 |
| NL2010225C2 (en) * | 2013-02-01 | 2014-08-04 | Conradus Ghosal Gho | Composition and method for preserving, transporting and storing living biological materials. |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
| HRP20240319T1 (hr) * | 2013-06-13 | 2024-05-24 | Akebia Therapeutics, Inc. | Pripravci i postupci za liječenje anemije |
| SG10202012791TA (en) | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| US10716783B2 (en) * | 2013-12-12 | 2020-07-21 | Cornell University | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom |
| EP2915878A1 (en) | 2014-03-07 | 2015-09-09 | Institut Pasteur | Method and device for conserving viable and functional human polymorphonuclear neutrophils |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| FI3795171T3 (fi) | 2014-07-11 | 2024-05-10 | Grifols Worldwide Operations Ltd | Transferriini käytettäväksi munuaissiirrossa |
| WO2016054806A1 (en) * | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | Substittued pyridine inhibitors of hif prolyl hydroxylase |
| HK1247201A1 (zh) | 2015-01-23 | 2018-09-21 | 阿克比治疗有限公司 | 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途 |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| SI3277270T1 (sl) | 2015-04-01 | 2022-04-29 | Akebia Therapeutics, Inc. | Sestavki in postopki za zdravljenje anemije |
| CN105296631A (zh) * | 2015-11-04 | 2016-02-03 | 吴艾霖 | 流式液相芯片急性高原病脯氨酰羟化酶基因rs480902位点检测试剂盒 |
| WO2017143131A1 (en) * | 2016-02-19 | 2017-08-24 | Cornell University | Hif-stabilization and prevention of hyperoxia-induced neonatal lung disease |
| CN108245687A (zh) * | 2016-12-29 | 2018-07-06 | 贾中芝 | 一种IpostC在抗肠再灌注损伤中所起作用的实验方法 |
| WO2019055490A1 (en) | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION |
| US11225660B2 (en) | 2017-10-12 | 2022-01-18 | Emory University | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors |
| CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US10500318B1 (en) * | 2018-07-03 | 2019-12-10 | Temple Therapeutics BV | Dosing regimens for treating hypoxia-associated tissue damage |
| WO2020156571A1 (zh) * | 2019-02-02 | 2020-08-06 | 杭州华东医药集团新药研究院有限公司 | 一种哒嗪衍生物及其制备方法和医药用途 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN113826614B (zh) * | 2021-09-30 | 2023-03-14 | 佛山市第一人民医院（中山大学附属佛山医院） | 一种器官保存液 |
| EP4463160A1 (en) * | 2022-01-13 | 2024-11-20 | Fibrogen, Inc. | Treatment for congestive heart failure |
| WO2024165507A1 (en) | 2023-02-06 | 2024-08-15 | Institut National de la Santé et de la Recherche Médicale | Use of hif-1α stabilizing agents for the treatment of type i interferonopathies |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| CA1261335A (en) * | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| GB8530602D0 (en) * | 1985-12-12 | 1986-01-22 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
| FI884418L (fi) * | 1987-10-05 | 1989-04-06 | Fujisawa Pharmaceutical Co | Hjaertskyddande aemne och ett terapeutiskt aemne foer ischemiska sjukdomar omfattande n-innehaollande heterocykliska foereningar, och ett foerfarande foer framstaellning av dessa foereningar. |
| DE4015255A1 (de) * | 1990-05-12 | 1991-11-14 | Hoechst Ag | Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5605662A (en) | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
| US5550124A (en) * | 1991-12-10 | 1996-08-27 | University Of Southern California | Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE59401923D1 (de) † | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE59401924D1 (de) | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| US5508463A (en) | 1994-03-17 | 1996-04-16 | Trustees Of The University Of Pennsylvania | α-aminophosphonates |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| EP0716077A1 (de) * | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| WO1997009976A2 (en) * | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| US5846528A (en) * | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
| KR20000065090A (ko) † | 1996-04-30 | 2000-11-06 | 훽스트 악티엔게젤샤프트 | 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도 |
| DE19650215A1 (de) * | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO1998029109A1 (en) * | 1996-12-30 | 1998-07-09 | Johns Hopkins University | Methods and compositions for identification of autoantigens |
| EP0878480A1 (en) * | 1997-05-14 | 1998-11-18 | H.W. Prof. Dr. Müller | A method for the improvement of neuronal regeneration |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| ATE255581T1 (de) | 1997-10-24 | 2003-12-15 | Fibrogen Inc | Phenanthrolin-derivate |
| US6200974B1 (en) | 1997-10-24 | 2001-03-13 | Zeneca Limited | Phenanthroline derivatives |
| US5916898A (en) | 1997-10-24 | 1999-06-29 | Zeneca Limited | Phenanthroline derivatives |
| IL136454A0 (en) * | 1997-12-04 | 2001-06-14 | Genzyme Corp | Compositions and methods for inducing gene expression |
| US6124131A (en) * | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
| CN1324234A (zh) * | 1998-09-25 | 2001-11-28 | 格利科克斯有限公司 | 果糖胺氧化酶,拮抗剂和抑制剂 |
| US6506936B1 (en) | 1999-02-25 | 2003-01-14 | Fibrogen, Inc. | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production |
| BR0010316A (pt) * | 1999-05-11 | 2004-04-27 | Ortho Mcnell Pharmaceutical In | Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente |
| GB9911047D0 (en) * | 1999-05-12 | 1999-07-14 | Isis Innovation | Assay method and means |
| PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| DE10010423A1 (de) * | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung |
| DE10010426A1 (de) * | 2000-03-03 | 2001-09-06 | Bayer Ag | Verwendung von 6-[4-Aminopheny]-dihydropyridazinonen |
| DE10010430A1 (de) * | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 5-Ethyl-dihydropyridazinone und ihre Verwendung |
| DE10010425A1 (de) * | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 5-Methyldihydropyridazinone und ihre Verwendung |
| EP1436258A4 (en) * | 2001-03-08 | 2005-03-23 | Univ Emory | PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| EP1379630B1 (en) † | 2001-03-21 | 2012-09-26 | Isis Innovation Limited | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
| US6878729B2 (en) | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| EP1406621A2 (en) * | 2001-06-26 | 2004-04-14 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
| US6566088B1 (en) * | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| CN100522946C (zh) * | 2001-12-06 | 2009-08-05 | 法布罗根股份有限公司 | 低氧诱导因子(HIF)α的稳定化 |
| US6994981B2 (en) * | 2002-02-19 | 2006-02-07 | The Buck Institute | Modulators of paraptosis and related methods |
| WO2003075910A1 (en) * | 2002-03-08 | 2003-09-18 | Protemix Corporation Limited | Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| BRPI0710527B8 (pt) * | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| EP2044005B8 (en) † | 2006-06-26 | 2012-12-05 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
-
2002
- 2002-12-06 CN CNB028240987A patent/CN100522946C/zh not_active Expired - Lifetime
- 2002-12-06 US US10/313,643 patent/US20030153503A1/en not_active Abandoned
- 2002-12-06 CN CNA028244745A patent/CN1602360A/zh active Pending
- 2002-12-06 JP JP2003554713A patent/JP2005524612A/ja active Pending
- 2002-12-06 JP JP2003550737A patent/JP5341293B2/ja not_active Expired - Lifetime
- 2002-12-06 EP EP10181768.2A patent/EP2289531B1/en not_active Revoked
- 2002-12-06 EP EP02797195.1A patent/EP1487472B1/en not_active Expired - Lifetime
- 2002-12-06 DK DK10181768.2T patent/DK2289531T3/en active
- 2002-12-06 EP EP19172616.5A patent/EP3520784A1/en not_active Withdrawn
- 2002-12-06 CN CN2010101113899A patent/CN102552262A/zh active Pending
- 2002-12-06 CA CA2916093A patent/CA2916093C/en not_active Expired - Lifetime
- 2002-12-06 AU AU2002362065A patent/AU2002362065B2/en not_active Expired
- 2002-12-06 ES ES02805548T patent/ES2414706T3/es not_active Expired - Lifetime
- 2002-12-06 DK DK10181796.3T patent/DK2298301T3/en active
- 2002-12-06 EP EP02805548A patent/EP1463823B1/en not_active Revoked
- 2002-12-06 AU AU2002357096A patent/AU2002357096B2/en not_active Expired
- 2002-12-06 CA CA3094774A patent/CA3094774A1/en not_active Expired - Lifetime
- 2002-12-06 WO PCT/US2002/038867 patent/WO2003049686A2/en not_active Ceased
- 2002-12-06 CN CN2010101114285A patent/CN102526045A/zh active Pending
- 2002-12-06 ES ES10181768.2T patent/ES2686625T3/es not_active Expired - Lifetime
- 2002-12-06 EP EP10180933A patent/EP2295059A3/en not_active Withdrawn
- 2002-12-06 US US10/313,551 patent/US20030176317A1/en not_active Abandoned
- 2002-12-06 ES ES10181796.3T patent/ES2686626T3/es not_active Expired - Lifetime
- 2002-12-06 HU HU0500643A patent/HU229475B1/hu unknown
- 2002-12-06 CN CN2010101113761A patent/CN102552263A/zh active Pending
- 2002-12-06 CA CA2467689A patent/CA2467689C/en not_active Expired - Lifetime
- 2002-12-06 EP EP10181843.3A patent/EP2324834B1/en not_active Revoked
- 2002-12-06 CN CN2010101113507A patent/CN102552261A/zh active Pending
- 2002-12-06 WO PCT/US2002/039163 patent/WO2003053997A2/en not_active Ceased
- 2002-12-06 CA CA2468083A patent/CA2468083C/en not_active Expired - Lifetime
- 2002-12-06 IL IL16208502A patent/IL162085A0/xx unknown
- 2002-12-06 CN CN2010101114088A patent/CN102526044A/zh active Pending
- 2002-12-06 DK DK02805548.1T patent/DK1463823T3/da active
- 2002-12-06 EP EP10181796.3A patent/EP2298301B2/en not_active Expired - Lifetime
-
2004
- 2004-05-20 IL IL162085A patent/IL162085A/en active IP Right Grant
- 2004-07-02 NO NO20042804A patent/NO343732B1/no not_active IP Right Cessation
-
2005
- 2005-12-05 JP JP2005351153A patent/JP4804131B2/ja not_active Expired - Lifetime
-
2006
- 2006-04-17 US US11/406,023 patent/US20060178316A1/en not_active Abandoned
- 2006-04-17 US US11/405,734 patent/US20060183695A1/en not_active Abandoned
- 2006-04-17 US US11/406,484 patent/US20060178317A1/en not_active Abandoned
- 2006-07-28 US US11/494,978 patent/US20060270699A1/en not_active Abandoned
- 2006-07-28 US US11/495,118 patent/US20060258702A1/en not_active Abandoned
- 2006-07-28 US US11/495,036 patent/US20060258660A1/en not_active Abandoned
-
2009
- 2009-01-02 AU AU2009200018A patent/AU2009200018C1/en not_active Expired
-
2010
- 2010-09-17 JP JP2010208681A patent/JP5469572B2/ja not_active Expired - Lifetime
- 2010-10-29 JP JP2010243226A patent/JP5498918B2/ja not_active Expired - Lifetime
- 2010-12-02 US US12/928,119 patent/US8466172B2/en not_active Expired - Fee Related
-
2011
- 2011-02-17 US US12/932,151 patent/US20110166178A1/en not_active Abandoned
-
2012
- 2012-09-13 US US13/614,917 patent/US20130203805A1/en not_active Abandoned
-
2013
- 2013-05-17 US US13/897,207 patent/US20130245037A1/en not_active Abandoned
-
2014
- 2014-07-16 US US14/332,814 patent/US20150080425A1/en not_active Abandoned
-
2017
- 2017-02-03 US US15/424,479 patent/US20170312268A1/en not_active Abandoned
-
2021
- 2021-08-05 US US17/394,602 patent/US20210369702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524612A5 (enExample) | ||
| JP6769982B2 (ja) | Ｒａｓ変異と関連するがんの治療方法 | |
| DE69434313T2 (de) | Superoxiddismutase memetika | |
| ES2750008T3 (es) | Células madre mesenquimatosas modificadas genéticamente que expresan klotho | |
| Li et al. | Mn (III) meso-tetrakis-(N-ethylpyridinium-2-yl) porphyrin mitigates total body irradiation-induced long-term bone marrow suppression | |
| Bernhardt et al. | Organ protection by hypoxia and hypoxia‐inducible factors | |
| CN112516336B (zh) | 一种用于急性肾损伤的纳米酶诊疗剂及其制备方法与应用 | |
| KR20120089250A (ko) | Ｃｋ２ 조절자로 복합 요법 | |
| RS52941B (sr) | Kombinacija alfa 7 nikotinskih agonista i antipsihotika | |
| CN103517902B (zh) | 治疗β-地中海型贫血及镰刀型贫血症的方法及组合物 | |
| WO2017197104A1 (en) | Yap1 inhibitors and methods | |
| JPWO2013054755A1 (ja) | エリスロポエチン産生促進剤 | |
| JP2021035977A (ja) | 新規治療用化合物及びその治療における使用 | |
| CN116726021A (zh) | 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途 | |
| CA2476825A1 (en) | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | |
| WO2020248240A1 (zh) | 痘苗病毒致炎兔皮提取物治疗癌症的用途 | |
| RU2654231C2 (ru) | Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты) | |
| CN102716123B (zh) | 一种用于治疗IgA肾病复方制剂 | |
| US20190350885A1 (en) | Prophylaxis treatment for acute myeloid leukemia | |
| US20220305027A1 (en) | Methods of controlling and improving brain health | |
| WO2020182144A1 (zh) | 用于治疗神经退行性疾病的化合物 | |
| WO2021062238A1 (en) | Methods and compositions for treating sickle cell disease and thalassemia | |
| Li et al. | Activating transcription factor 4 in erythroid development and β-thalassemia: a powerful regulator with therapeutic potential | |
| JP7719787B2 (ja) | アルテミシニン化合物、５－アミノレブリン酸またはメチル－５－アミノレブリン酸、および化学療法剤の医薬配合物 | |
| EP2870135A1 (en) | Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors |